Chairman & CEO: Garo Armen

Advent Contact: Shahzad Malik

Broad platform of antibodies and vaccines targeting the immune system for cancer therapy

Agenus is developing a clinical pipeline of proprietary cancer vaccines and monoclonal antibodies for use individually and in combination in the treatment of a range of cancers. The company has established collaborations with Merck and Incyte on some of its checkpoint modulators.

Agenus acquired 4-Antibody, an Advent portfolio company, in 2014. Agenus is listed on NASDAQ.